|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older. LUZU is indicated for topical use only and is not indicated for ophthalmic, oral or intravaginal use. LUZU is the only azole with once-daily, 2-week dosing for the treatment of interdigital tinea pedis. LUZU achieved complete clearance* vs vehicle: 20% vs 2% (respectively). |
||||||||||||||
|
||||||||||||||
|
Indications and Usage LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older. Important Safety Information LUZU is indicated for topical use only and is not indicated for ophthalmic, oral or intravaginal use. LUZU should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when LUZU is prescribed for nursing mothers. The most common adverse reactions in clinical trials were application site reactions, which occurred in less than 1% of subjects in both LUZU and vehicle arms. Most adverse reactions were mild in severity. |
||||||||||||||
| * |
Complete clearance=mycological cure (negative KOH exam and negative fungal culture) plus clinical cure (absence of erythema, scaling, and pruritus).
|
|||||||||||||
| † |
Not valid for patients reimbursed in whole or part by federal health care programs, including Medicare, Medicaid, CHAMPUS, the Department of Veterans Affairs, state maternal and child health block grant programs under 42 U.S.C. 701 et. seq., state social service block grant programs under 42 U.S.C. section 1397 et. seq. or any other similar federal or state health care program. Void where prohibited by law, taxed or restricted. Void outside the United States. See rebate card for full eligibility terms and conditions.
Patients with questions should call 855-264-0299. Valeant Pharmaceuticals reserves the right to rescind, revoke or amend this offer at any time. Please see full Prescribing Information available at LUZURX.com. Reference: LUZU [prescribing information]. Bridgewater, NJ: Medicis, a division of Valeant Pharmaceuticals; 2013. You have the right to opt-out of receiving unsolicited advertisements by e-mail. You may contact us with your opt-out request, along with the e-mail to which your request relates, by telephone at Except as otherwise indicated, all product names, slogans, and other marks are trademarks of the Valeant family of companies.
|
|||||||||||||
